Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Chief Scientific Officer | August 10, 2017 | August 11, 2017 |
| HTG MOLECULAR DIAGNOSTICS, INCHTGM · Entity 112530 | Director | August 18, 2022 | August 22, 2022 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director · President | January 03, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHINOOK THERAPEUTICS, INC.
Report date August 10, 2017 · Filed August 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,900 |
Ending reported balance
After 2017-08-11 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2017-08-10 · Exercise / conversion · Acquired 40,912 · Balance 80,812 Row 2 · 2017-08-10 · Sale · Disposed 40,912 · Balance 39,900 F1: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2017-08-11 · Exercise / conversion · Acquired 9,088 · Balance 48,988 Row 4 · 2017-08-11 · Sale · Disposed 9,088 · Balance 39,900 F1: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $11.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2024-07-30 | Direct | 135,416 |
Reported balance
After 2017-08-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-08-10 · Exercise / conversion · Disposed 40,912 · Balance 135,416 F4: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of July 31, 2014. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2024-07-30 | Direct | 126,328 |
Reported balance
After 2017-08-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-08-11 · Exercise / conversion · Disposed 9,088 · Balance 126,328 F4: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of July 31, 2014. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2017.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.10 to $11.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of July 31, 2014.
HTG MOLECULAR DIAGNOSTICS, INC
Report date August 18, 2022 · Filed August 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2032-08-17 | Direct | 8,000 |
Reported balance
After 2022-08-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-18 · Grant · Acquired 8,000 · Balance 8,000 F1: One-third of the shares will vest twelve months after August 18, 2022 and the remaining shares will vest monthly in equal installments over a two year period such that the stock option is fully vested on the third anniversary of August 18, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of the shares will vest twelve months after August 18, 2022 and the remaining shares will vest monthly in equal installments over a two year period such that the stock option is fully vested on the third anniversary of August 18, 2022.
Tempest Therapeutics, Inc.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2033-01-02 | Direct | 102,700 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 102,700 · Balance 102,700 F1: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2017 Filed Jan 5, 2017 17:15 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 25,000 | $0.52 | $13,000.00 |
DisclosureSEC source: 0001209191-17-002230 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 21:05 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (right to buy) · Derivative | 29,800 | $0.00 Strike: $11.15 | $0.00 |
DisclosureSEC source: 0001209191-16-155281 · doc4.xml · derivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,800 Underlying: Common Stock · 29,800 shares Expires 2026-12-11 F1 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of December 12, 2016. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,875 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-16-153512 · doc4.xml · derivative · entry 7 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,736 Underlying: Common Stock · 2,875 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the Option were fully vested as of September 1, 2015. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,262 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-16-153512 · doc4.xml · derivative · entry 6 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,422 Underlying: Common Stock · 8,262 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the Option were fully vested as of December 31, 2015. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,863 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-16-153512 · doc4.xml · derivative · entry 5 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,220 Underlying: Common Stock · 13,863 shares Expires 2025-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 25,000 | $10.94 | $273,500.00 |
DisclosureSEC source: 0001209191-16-153512 · doc4.xml · nonDerivative · entry 4 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.55 to $11.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 2,875 | $0.52 | $1,495.00 |
DisclosureSEC source: 0001209191-16-153512 · doc4.xml · nonDerivative · entry 3 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 8,262 | $0.52 | $4,296.24 |
DisclosureSEC source: 0001209191-16-153512 · doc4.xml · nonDerivative · entry 2 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:21 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 13,863 | $1.45 | $20,101.35 |
DisclosureSEC source: 0001209191-16-153512 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 19:00 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,938 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-16-149950 · doc4.xml · derivative · entry 5 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,684 Underlying: Common Stock · 3,938 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the Option were fully vested as of December 31, 2015. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 19:00 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 21,062 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-16-149950 · doc4.xml · derivative · entry 4 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,083 Underlying: Common Stock · 21,062 shares Expires 2025-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 19:00 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 25,000 | $14.78 | $369,407.50 |
DisclosureSEC source: 0001209191-16-149950 · doc4.xml · nonDerivative · entry 3 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.20 to $15.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 19:00 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 3,938 | $0.52 | $2,047.76 |
DisclosureSEC source: 0001209191-16-149950 · doc4.xml · nonDerivative · entry 2 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 19:00 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 21,062 | $1.45 | $30,539.90 |
DisclosureSEC source: 0001209191-16-149950 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:18 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,476 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001209191-16-145071 · doc4.xml · derivative · entry 5 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,622 Underlying: Common Stock · 9,476 shares Expires 2021-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the Option were fully vested as of December 31, 2015. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:18 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,524 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-16-145071 · doc4.xml · derivative · entry 4 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,145 Underlying: Common Stock · 15,524 shares Expires 2025-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:18 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 25,000 | $12.68 | $316,907.50 |
DisclosureSEC source: 0001209191-16-145071 · doc4.xml · nonDerivative · entry 3 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · kind: The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.41 to $12.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:18 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 9,476 | $0.52 | $4,927.52 |
DisclosureSEC source: 0001209191-16-145071 · doc4.xml · nonDerivative · entry 2 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:18 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 15,524 | $1.45 | $22,509.80 |
DisclosureSEC source: 0001209191-16-145071 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 16:13 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantCommon Stock | 39,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-141390 · doc4.xml · nonDerivative · entry 1 Dubensky Thomas W. · CIK 0001635590 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 F1 · shares: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.